Immunotherapy for Squamous Esophageal Cancer: A Review
Esophageal squamous cell carcinoma (ESCC) is a rare gastrointestinal tumour with high mortality. A multimodality treatment based on chemoradiotherapy followed by surgery is the standard of care in the case of non-metastatic disease; chemotherapy has historically been the gold standard in the metasta...
Main Authors: | Angelica Petrillo, Elizabeth C. Smyth |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/12/6/862 |
Similar Items
-
Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
by: Yi-Min Gu, et al.
Published: (2022-05-01) -
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data
by: Kim Y, et al.
Published: (2023-05-01) -
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
by: Amy L. Cummings, et al.
Published: (2017-08-01) -
Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
by: Daniele Raggi, et al.
Published: (2021-08-01) -
Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?
by: Himmelsbach V, et al.
Published: (2024-02-01)